此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

早产新生儿的独家母乳和早期血管老化风险因素 (NEOVASC) (NEOVASC)

2026年9月15日 更新者:Ursula Kohlendorfer、Prolacta Bioscience

早产新生儿纯母乳饮食对早期血管老化危险因素 (NEOVASC) 的影响

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

研究概览

地位

招聘中

详细说明

Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.

The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.

The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.

研究类型

介入性

注册 (估计的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Tyrol
      • Innsbruck、Tyrol、奥地利、A-6020
        • 招聘中
        • Medical University of Innsbruck
        • 接触:
        • 接触:
        • 首席研究员:
          • Christoph Binder, MD
        • 首席研究员:
          • Martin Wald, MD
        • 首席研究员:
          • Burkhard Simma, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

1天 至 5年 (孩子)

接受健康志愿者

不

有资格学习的性别

全部

描述

Preterm-born group:

Inclusion Criteria:

  1. Extremely preterm infants with a birth weight of 500-1250g.
  2. Feeding is NPO or exclusive human milk prior to enrollment.
  3. Parent(s) willing to sign informed consent.-

Exclusion Criteria:

  1. Infants with a birth weight <500g or >1250g
  2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
  3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
  4. Presence of major congenital malformation.
  5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
  6. Parent(s) not willing to sign informed consent.
  7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).

Term-born group:

Inclusion criteria

  1. Term-born children with an adequate birth weight
  2. Parent(s) willing to sign informed consent

Exclusion criteria

  1. Subjects with acute or chronic illness
  2. Parent(s) not willing to sign informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
有源比较器:Randomized study product group

receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

有源比较器:Randomized control group

receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

无干预:Term control group

Term-born controls as a reference group for outcome parameters

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Fasting blood glucose
大体时间:"First day of life" up to "five years of life"

Primary outcome is the difference in fasting blood glucose at five years of age

"First day of life" up to "five years of life"
Blood pressure
大体时间:"First day of life" up to "five years"

Primary outcome is the difference in blood pressure at five years of age

"First day of life" up to "five years"
Distensibility of aorta
大体时间:"First day of life" up to "five years"

Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age

"First day of life" up to "five years"

次要结果测量

结果测量
措施说明
大体时间
Fasting blood glucose
大体时间:"First day of life" up to "24 months"

Secondary outcome is fasting glucose at a corrected age of one and two years.

"First day of life" up to "24 months"
Blood pressure
大体时间:"First day of life" up to "24 months"

Secondary outcome is blood pressure at a corrected age of one and two years.

"First day of life" up to "24 months"
BMI
大体时间:"First day of life" up to "five years"

Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"First day of life" up to "five years"
Insulin sensitivity
大体时间:"First day of life" up to "five years"

Secondary outcome is insulin sensitivity at five years of age

"First day of life" up to "five years"
Lipid profile
大体时间:"First day of life" up to "five years"

Secondary outcome is lipid profile at five years of age

"First day of life" up to "five years"

其他结果措施

结果测量
措施说明
大体时间
Fasting blood glucose
大体时间:"five years of age"

Difference in fasting blood glucose between preterm- and term-born children at five years of age

"five years of age"
Blood pressure
大体时间:"five years of age"

Difference in blood pressure between preterm- and term-born children at five years of age

"five years of age"
Distensibility of the descending aorta
大体时间:"five years of age"

Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children

"five years of age"
BMI
大体时间:"five years of age"

Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"five years of age"
Insulin sensitivity
大体时间:"five years of age"

Difference in insulin sensitivity between preterm- and term-born children at five years of age

"five years of age"
Lipid profile
大体时间:"five years of age"

Difference in lipid profile between preterm- and term-born children at five years of age

"five years of age"

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Ursula Kiechl-Kohlendorfer, MD, MSc、Medical University Innsbruck

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年10月9日

初级完成 (估计的)

2028年6月1日

研究完成 (估计的)

2028年6月1日

研究注册日期

首次提交

2020年5月26日

首先提交符合 QC 标准的

2020年5月30日

首次发布 (实际的)

2020年6月4日

研究记录更新

最后更新发布 (实际的)

2026年9月18日

上次提交的符合 QC 标准的更新

2026年9月15日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NEOVASC
  • 868624 (其他赠款/资助编号:Austrian Research Promotion Agency)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅